Marker Therapeutics Inc. Common Stock (MRKR)

About MRKR

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and ki…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

5

Website

markertherapeutics.com/

Fundamentals

1-day range

$1.35$1.5

Market cap

$18.67M

P/E (trailing)

—

P/E (forward)

-2.58

EPS (trailing)

$-0.90

Dividend yield

—

Beta

1.48

Avg. volume

64.9K

Dividend pay date

September 16, 2016

Forecasts

3 analyst ratings

Marker Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• MRKR

  Marker Therapeutics Inc. Common Stock

  $1.37

  ▼ 7.12%
  Market cap $18.67MP/E —
  $0.8099$2.46
• NRSN

  NeuroSense Therapeutics Ltd. Ordinary Shares

  $0.4301

  ▼ 2.03%
  Market cap $19.00MP/E —
  $0.25$1.98
• NCEL

  NewcelX Ltd. Ordinary Shares

  $3.19

  ▼ 6.73%
  Market cap $17.98MP/E —
  $1.83$24.6
• RKTO

  Rocket One Inc. Common Stock

  $0.7021

  ▼ 2.76%
  Market cap $19.75MP/E —
  $0.691501$2.45
• LPCN

  Lipocine Inc. Common Stock

  $2.2

  ▼ 1.35%
  Market cap $17.56MP/E —
  $1.81$12.37
• GRDX

  GridAI Technologies Corp. Common Stock

  $4.05

  ▲ 1.00%
  Market cap $19.91MP/E —
  $1.65$6.93
• DARE

  Dare Bioscience Inc. Common Stock

  $0.7437

  ▲ 0.64%
  Market cap $19.92MP/E —
  $0.72$3.78

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Tuesday's After-Market Session
  Benzinga · 8/25/2026

Institutional Ownership

March 31, 2026

Total shares held

3.81M

Total value held

$4.94M

Institutional holders

33